Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bright-Eyed And Bushy Tailed: Purdue Launches Intermezzo

This article was originally published in The Pink Sheet Daily

Executive Summary

Purdue Pharma launched Transcept Pharmaceutical’s Intermezzo, a low-dose sublingual tablet version of the generic sleep aid zolpidem, for middle-of-the-night awakenings April 5. Priced at a wholesale acquisition cost of $6.45 per tablet, the drug could face an uphill commercial road competing against generics.

You may also be interested in...

Transcept/Purdue’s Intermezzo Gets $29 Million Re-launch

The companies will bulk up their sales force and begin a direct-to-consumer campaign in an effort to boost sales for their sleep aid, which has gotten off to a slow start since its launch in April.

Financings Of The Fortnight: Biotech IPO Trends Continue With Supernus’ Offering – Haircuts, Insider Buys

Plus news on recent financing activity by Argos, Telstar, Castlight Health and Transcept.

Transcept Gains Long-Delayed Approval Of Intermezzo

Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts